Gold Sponsors

MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across Oncology, Respiratory, Cardiovascular & Metabolic Diseases, and Infection and Vaccines. For more information, please visit www.medimmune.com. 

The parent company, AstraZeneca, is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.  For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Seqirus is part of CSL Limited a global speciality biopharmaceutical company headquartered in Melbourne, Australia. The CSL Group operates in more than 60 countries and employs over 20,000 people. Seqirus was established on 31 July 2015 following CSL’s acquisition of the Novartis influenza vaccines business and its subsequent integration with bioCSL.          

Seqirus is the second largest influenza vaccine manufacturer in the world, and the only vaccine company solely dedicated to influenza.  It has deep technical expertise in the science and manufacture of influenza vaccines and operates influenza vaccine manufacturing facilities in the UK (Liverpool), US (Holly Springs) and Australia (Melbourne), as well as R&D hubs in Boston, Amsterdam and Melbourne. 

Seqirus utilises both egg and cell-based production technologies and has commercialised the only adjuvanted seasonal influenza vaccine for elderly and paediatric populations. The company’s R&D pipeline is focussed on age and geographic expansion of its current product portfolio and includes stage research into novel sources of antigen and new delivery technologies.

As a CSL company, Seqirus has a rich heritage in influenza, dating right back to the 1918 Spanish Influenza Pandemic. Today, the company provides pandemic preparedness and response solutions to government partners all around the world.  Seqirus also continues to manufacture unique products for the Australian Government including Q fever vaccine and a range of antivenoms.

For more information about Seqirus visit  www.seqirus.com

Silver Sponsors

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. 

For more information, please visit www.roche.com

At Sanofi Pasteur, the vaccines division of Sanofi, we believe in a world where no one suffers or dies from a vaccine preventable disease. We provide more than one billion doses of vaccines every year, helping protect as many as half a billion lives each year against life-threatening infectious diseases at every stage of life. As a world leader in the vaccines industry, Sanofi Pasteur produces a portfolio of vaccines that matches its areas of expertise and meets public-health demand. With our 15,000 employees worldwide, we seek to extend the protective power of vaccination to new infectious diseases while continuously improving existing vaccines to enhance health and wellbeing. The company's heritage, to develop vaccines that help protect life, dates back more than a century.

Bronze Sponsor

GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

GSK is one of the world’s leading vaccine companies, involved in vaccine research, development and production. We have 14 vaccines in development and our portfolio of 41 vaccines prevent illnesses such as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza and bacterial meningitis. Globally, we have more than 16,000 people working to deliver more than 2 (2.3) million vaccines every day, to people in 166 countries.

For further information, please visit www.gsk.com

Company website: www.thermofisher.com